NCT01132573: Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia |
|
|
| Completed | 1 | 27 | US | entinostat, HDAC inhibitor SNDX-275, SNDX-275, clofarabine, CAFdA, Clofarex, Clolar, pharmacological study, pharmacological studies, laboratory biomarker analysis | National Cancer Institute (NCI) | Acute Leukemias of Ambiguous Lineage, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia | 06/14 | | | |
